Sugi Predict

Sugi Predict / Compounds / SCHEMBL17278262

SCHEMBL17278262

SCHEMBL17278262

Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCOC(C)C)CC2)n1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 11/20 0.81
▸ SRC P12931 8/20 0.81
▸ LCK P06239 4/20 0.81
▸ PKMYT1 Q99640 3/20 0.81
▸ EPHB6 O15197 2/20 0.81
▸ EGFR P00533 2/20 0.81
▸ FYN P06241 2/20 0.81
▸ CSF1R P07333 2/20 0.81
▸ YES1 P07947 2/20 0.81
▸ LYN P07948 2/20 0.81
▸ RET P07949 2/20 0.81
▸ HCK P08631 2/20 0.81
▸ KIT P10721 2/20 0.81
▸ BCR P11274 2/20 0.81
▸ BRAF P15056 2/20 0.81
▸ EPHA1 P21709 2/20 0.81
▸ EPHA2 P29317 2/20 0.81
▸ EPHA3 P29320 2/20 0.81
▸ EPHA8 P29322 2/20 0.81
▸ EPHB2 P29323 2/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17663528 0.93 ABL1 (0.86) ABL1SRCLCKPKMYT1EPHB6
SCHEMBL16582217 0.92 ABL1 (0.85) ABL1SRCLCKPKMYT1EPHB6
SCHEMBL17620522 0.92 ABL1 (0.93) ABL1SRCLCKPKMYT1EPHB6
SCHEMBL5945218 0.92 ABL1 (0.77) ABL1SRCLCKPKMYT1EPHB6
SCHEMBL21350021 0.92 ABL1 (0.82) ABL1SRCLCKPKMYT1EPHB6
SCHEMBL21349527 0.91 ABL1 (0.84) ABL1SRCLCKPKMYT1EPHB6
SCHEMBL21349290 0.91 ABL1 (0.84) ABL1SRCLCKPKMYT1EPHB6
SCHEMBL10138254 0.91 ABL1 (0.78) ABL1SRCLCKPKMYT1EPHB6
SCHEMBL17367319 0.91 ABL1 (0.78) ABL1SRCLCKPKMYT1EPHB6
SCHEMBL17347934 0.91 ABL1 (0.79) ABL1SRCLCKPKMYT1EPHB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193242-A1 IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2022-06-23 — — US disclosed
US-11040106-B2 Conjugates of kinase inhibitors and cyanine dyes Small Molecule PPI Mimics LLC (US) 2021-06-22 — — US disclosed
US-20190343958-A1 CONJUGATES OF KINASE INHIBITORS AND CYANINE DYES UNITED STATES GOVERNMENT 2019-11-14 — — US disclosed
EP-2947070-A1 MULTI-TARGETED UBENIMEX PRODRUG DERIVATIVE AND PREPARATION METHOD AND USE THEREOF Weifang Bochuang International Academy of Biotechnology and Medicine (CN) 2015-11-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193242-A1 IMMUNOPHILIN-DEPENDENT INHIBITORS AND USES THEREOF CD74, CD2BP2, SERPINB1 ABL1 2123/4885SRC 1950/4885LCK 382/4885
US-11040106-B2 Conjugates of kinase inhibitors and cyanine dyes ABL1, MAP3K20, MAP4K2 ABL1 1/4885SRC 24/4885LCK 45/4885
US-20190343958-A1 CONJUGATES OF KINASE INHIBITORS AND CYANINE DYES ABL1, MAP3K20, MAP4K2 ABL1 1/4885SRC 24/4885LCK 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.